PMID- 32871976
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 33
DP  - 2020 Aug 14
TI  - HER2-positive pure mucinous breast carcinoma: A case report and literature 
      review.
PG  - e20996
LID - 10.1097/MD.0000000000020996 [doi]
LID - e20996
AB  - INTRODUCTION: Pure mucinous carcinoma is a rare type of breast carcinoma, but it 
      usually has a favorable prognosis. Tumors of pure mucinous carcinoma are 
      typically positive for both estrogen receptor (ER) and progesterone receptor 
      (PR), and they do not commonly overexpress human epidermal growth factor receptor 
      2 (HER2). However, when tumors have HER2 overexpression and are progesterone 
      receptor negative, the prognosis is worse. PATIENT CONCERNS: A 59-year-old female 
      reported a slow growth mass of 3 years, which was radiologically diagnosed as 
      fibroadenoma at another institution. The patient came to our institution for 
      treatment and follow-up. She had no salient past history. DIAGNOSIS: Excisional 
      biopsy revealed a pure mucinous breast carcinoma that was ER (100%, 
      moderate-strong intensity), PR(-), 5% Ki-67 (+), and HER2(3+) by 
      immunohistochemistry. The HER2 gene was found to be amplified by fluorescence in 
      situ hybridization (FISH). The clinical staging was T2N0M0, with pathological 
      grade I, subtype luminal B. INTERVENTIONS: After a modified radical mastectomy, 
      she received four 21-day cycles of intravenous docetaxel (75 mg/m), intravenous 
      cyclophosphamide (600 mg/m), and intravenous trastuzumab (8 mg/kg) (loading dose) 
      on day 1 followed by 6 mg/kg every 3 weeks to complete a full year of treatment. 
      She then received 2.5 mg of letrozole daily for 5 years. OUTCOMES: After 
      following up for 2 years, the patient's outcome was survival without recurrence. 
      Cardiac ultrasounds were performed every 3 months and there was no change in the 
      left ventricular ejection fraction (LEVF). CONCLUSION: It is essential to 
      correctly diagnose the ER(+), PR(-) HER2(+) subtype in mucinous carcinoma. This 
      type should be treated with chemotherapy and anti-HER2 therapy, as well as 
      aromatase inhibitor endocrine therapy.
FAU - Zhao, Xingjuan
AU  - Zhao X
AD  - Department of Mammary Gland.
FAU - Yang, Xuan
AU  - Yang X
AD  - Department of Mammary Gland.
FAU - Gao, Runfang
AU  - Gao R
AD  - Department of Mammary Gland.
FAU - Zhai, Liqin
AU  - Zhai L
AD  - Department of Pathology, Shanxi People's Hospital, Taiyuan.
FAU - Yang, Lizhu
AU  - Yang L
AD  - Department of Pathology, Shanxi People's Hospital, Taiyuan.
FAU - Yu, Keda
AU  - Yu K
AD  - Department of Mammary Gland, Fudan University Cancer Hospital, Shanghai, China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma, Mucinous/diagnosis/*genetics/pathology/*therapy
MH  - Breast Neoplasms/diagnosis/*genetics/pathology/*therapy
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Receptor, ErbB-2/*genetics
MH  - Receptors, Estrogen/genetics
MH  - Receptors, Progesterone/genetics
PMC - PMC7437824
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/18 06:00
PMCR- 2020/08/14
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PHST- 2020/08/14 00:00 [pmc-release]
AID - 00005792-202008140-00010 [pii]
AID - MD-D-19-08985 [pii]
AID - 10.1097/MD.0000000000020996 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 14;99(33):e20996. doi: 
      10.1097/MD.0000000000020996.